The selloff highlights the growing risks insurers face as Washington tightens its grip on Medicare Advantage payments.

CMS’s proposal to limit chart reviews could rein in billions in Medicare Advantage overpayments, despite sharp industry backlash.

Analysts questioned whether Trump’s “Great Healthcare Plan” can deliver real relief, citing limited legislative pathways and modest potential impact.

Escalating tariffs, Iran-related tensions, and defense spending are emerging as key drivers of volatility and higher yields.

Pharmaceutical executives are entering 2026 with renewed confidence as pricing and tariff pressures from Washington fade, lifting investor sentiment ahead of the J.P. Morgan Healthcare Conference.

President Donald Trump’s effort to broker an end to the war in Ukraine hit new uncertainty after Russian President Vladimir Putin said he would revisit Moscow’s negotiating stance following an alleged Ukrainian drone attack—claims Kyiv has dismissed as false.

The administration announced that pharmaceutical companies agreed to reduce Medicare prices on 15 high-cost drugs—changes that could save taxpayers billions when they take effect in 2027.

Henrietta Treyz, Co-Founder at Veda Partners, weighs in on the implications of the Supreme Court’s upcoming ruling on presidential tariff authority, as the EU raises concerns over the expanding list of its products facing steep U.S. metal tariffs.

Henrietta Treyz, Co-Founder at Veda Partners, weighs in on the latest developments surrounding the U.S. government shutdown.